Molecular imaging of regional brain tumor biology

Journal of Cellular Biochemistry

Volumn , Issue SUPPL. 39, 2002, Pages 25-35

  Spence, A M ^a,b   Muzi, M ^a   Krohn, K A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brain neoplasm; Glioma; Glucose metabolism; Lumped constant; Oxygen metabolism; PET; Radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; OXYGEN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BRAIN METABOLISM; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; DNA SYNTHESIS; ENERGY METABOLISM; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; HYPOXIA; IMAGING; MOLECULAR BIOLOGY; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; ANIMAL; ANOXIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; ANOXIA; BRAIN NEOPLASMS; GLIOMA; HUMANS; OXYGEN; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036987011     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10406     Document Type: Article

References (63)

1. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO, Inscoe SW, Black JL, van Zijl PC, Moonen CT. 1990. Metabolism of human gliomas: Assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 177:633-641.
2. Allen N. 1972. Respiration and oxidative metabolism of brain tumors. In: Kirsch WM, Paoletti EG, Paoletti P, editors. The Experimental Biology of Brain Tumors. Springfield; Charles C Thomas. pp 243-274.
3. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD. 1997. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115-126.
4. Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, Comar D. 1984. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: A positron tomography study. J Cerebral Blood Flow Metab 4:140-149.
5. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A. 2002. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8:2766-2774.
6. Bennett MJ, Timperley WR, Taylor CB, Hill AS. 1978. Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur J Cancer 14:189-193.
7. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. 1999. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117.
8. 18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast, and macrophage cells in vitro. Nucl Med Biology submitted.
9. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. 1998. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 46:229-237.
10. Crane PD, Pardridge WM, Braun LD, Nyerges AM, Oldendorf WH. 1981. The interaction of transport and metabolism on brain glucose utilization: A reevaluation of the lumped constant. J Neurochem 36:1601-1604.
11. Curran WJJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF. 1993. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710.
12. Davis LW. 1989. Malignant glioma - A nemesis which requires clinical and basic investigation in radiation oncology. Int J Radiat Oncol Biol Phys 16:1355-1365.
13. De Witte O, Hildebrand J, Luxen A, Goldman S. 1994. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74:2836-2842.
14. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. 2001. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805-1814.
15. 18F] fluorodeoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest Radiol 22:360-371.
16. Di Chiro G, Brooks RA. 1988. PET quantitation: Blessing and curse. J Nucl Med 29:1603-1604.
17. Doenst T, Taegtmeyer H. 1998. Complexities underlying the quantitative determination of myocardial glucose uptake with 2-deoxyglucose. J Mol Cell Cardiol 30:1595-1604.
18. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA. 1999. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 59: 615-621.
19. Fredriksson A, Johnstrom P, Thorell JO, von Heijne G, Hassan M, Eksborg S, Kogner P, Borgstrom P, Ingvar M, Stone-Elander S. 1999. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 65:165-174.
20. Fujibayashi Y, Waki A, Sakahara H, Konishi J, Yonekura Y, Ishii Y, Yokoyama A. 1997. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: From gene expression to deoxyglucose uptake. Radiat Res 147:729-734.
21. Furuta M, Hasegawa M, Hayakawa K, Yamakawa M, Ishikawa H, Nonaka T, Mitsuhashi N, Niibe H. 1997. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 24:435-438.
22. Gaitonde MK, Evison E, Evans GM. 1983. The rate of utilization of glucose via hexosemonophosphate shunt in brain. J Neurochem 41:1253-1260.
23. Gerhardt W, Clausen J, Christensen E, Riishede J. 1967. Lactate dehydrogenase isoenzymes in the diagnosis of human benign and malignant brain tumors. J Natl Cancer Inst 38:343-357.
24. Graham MM, Muzi M, Spence AM, O'Sullivan F, Lewellen TK, Link JM, Krohn KA. 2002. The fluorodeoxyglucose lumped constant in normal human brain. J Nucl Med 43:1157-1166.
25. Griffin TW, Davis R, Laramore G, Hendrickson F, Rodrigues Antunez A, Hussey D, Nelson J. 1983. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 6:661-667.
26. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altmann A, Kahn B, van Kaick G. 1994. Fluorodeoxyglucose uptake in vitro: Aspects of method and effects of treatment with gemcitabine. J Nucl Med 35:1842-1850.
27. Hasegawa M, Mitsuhashi N, Yamakawa M, Furuta M, Maebayashi K, Imai R, Hayakawa K, Niibe H. 1997. p53 protein expression and radiation-induced apoptosis in human tumors transplanted to nude mice. Radiat Med 15:171-176.
28. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785.
29. Herholz K, Heindel W, Luyten PR, den Hollander JA, Pietrzyk U, Voges J, Kugel H, Friedmann G, Heiss WD. 1992. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 31:319-327.
30. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods. Eur J Nucl Med 27:731-743.
31. Holzer T, Herholz K, Jeske J, Heiss WD. 1993. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17:681-687.
32. Hossmann KA, Mies G, Paschen W, Szabo L, Dolan E, Wechsler W. 1986. Regional metabolism of experimental brain tumors. Acta Neuropathol Berl 69:139-147.
33. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA. 1995. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33: 391-398.
34. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. 1992. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972-1980.
35. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM. 1999. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43: 79-88.
36. Liu RS, Chu LS, Chu YK, Yen SH, Liao SQ, Yeh SH. 1999. Does β-oxidation occur in malignant neoplasm? A concurrent [C-11]acetate and [F-18]MISO study (abstract). J Nucl Med 40(suppl):239p.
37. Maruyama I, Sadato N, Waki A, Tsuchida T, Yoshida M, Fujibayashi Y, Ishii Y, Kubota T, Yonekura Y. 1999. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: A PET study. J Nucl Med 40:1085-1090.
38. Mathias CJ, Welch MJ, Kilbourn MR, Jerabek PA, Patrick TB, Raichle ME, Krohn KA, Rasey JS, Shaw DW. 1987. Radiolabeled hypoxic cell sensitizers: Tracers for assessment of ischemia. Life Sci 41:199-206.
39. Muzi M, Freeman SD, Burrows RC, Wiseman RW, Link JM, Krohn KA, Graham MM, Spence AM. 2001. Kinetic characterization of hexokinase isoenzymes from glioma cells: Implications for FDG imaging of human brain tumors. Nucl Med Biol 28:107-116.
40. Ogawa T, Uemura K, Shishido F, Yamaguchi T, Murakami M, Inugami A, Kanno I, Sasaki H, Kato T, Hirata K, Kowada M, Mineura K, Yasuda T. 1988. Changes of cerebral blood flow and oxygen and glucose metabolism following radiochemotherapy of gliomas: A PET study. J Comput Assist Tomogr 12:290-297.
41. Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, Sasaki T. 2001. Brain tumour imaging with carbon-11 choline: Comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 28:1664-1670.
42. Oudard S. 1996. High glycolysis in gliomas despite low hexokinase transcription and activity correlated with chromosome 10 loss. Br J Cancer 74:839-845.
43. Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B, Poupon MF. 1995. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62:216-222.
44. 13F-FDG PET in gliomas. J Nucl Med 43:111P.
45. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM. 1985. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62:816-822.
46. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29:427-431.
47. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. 1997. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: A comparison of fluorodeoxyglucose, L-methionine, and thymidine. J Nucl Med 38:280-287.
48. Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, Thomas DG, Jones T. 1983. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14:614-626.
49. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET). J Nucl Med (Abstract 250) 42:267P.
50. Sloan AE, Shields AF, Kupsky W, Heilbrun N, Abrams J, Barger G, Kuntzsch M, Reimold M, Machulla H-J, Bares R. 2001. Superiority of [F-18]FLT-PET compared to FDG PET in assessing proliferative activity and tumor physiology in primary and recurrent intracranial gliomas. Neuro-Oncology (Abstract 313) 3:345.
51. Smith TA, Maisey NR, Titley JC, Jackson LE, Leach MO, Ronen SM. 2000. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J Nucl Med 41:1753-1759.
52. Sokoloff L. 1981. The deoxyglucose method: Theory and practice. Eur Neurol 20:137-145.
53. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. 1977. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916.
54. Spence AM, Graham MM, Abbott GL, Muzi M, Krohn KA, Kapoor R. 1988. Assessment of deoxyglucose and glucose transport in a rat transplanted brain tumor model. J Nucl Med 29:920.
55. Spence AM, Graham MM, Muzi M, Freeman SD, Link JM, Grierson JR, O'Sullivan F, Stein D, Abbott GL, Krohn KA. 1997. Feasibility of imaging pentose cycle glucose metabolism in gliomas with PET: Studies in rat brain tumor models. J Nucl Med 38:617-624.
56. Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, Lewellen TK, Lewellen B, Freeman SD, Berger MS, Ojemann GA. 1998. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose, and FDG: Analysis of the FDG lumped constant. J Nucl Med 39:440-448.
57. Spence AM, Muzi M, Graham MM, O'Sullivan F, Link JM, Lewellen TK, Lewellen B, Freeman SD, Mankoff DA, Eary JF, Krohn KA. 2002a. FDG and glucose uptake in malignant gliomas before and after radiotherapy: Correlation with outcome. Clinical Cancer Res 8:971-979.
58. Spence AM, Muzi M, O'Sullivan F, Mankoff DA, Minoshima S, Krohn KA. 2002b. FDG-PET of malignant gliomas at delayed intervals: Improved distinction between tumor and gray matter. 49th Annual Meeting of the Society of Nuclear Medicine. Los Angeles.
59. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily R, Hummel S, Scharnhorst J, Krohn KA, Spence AM. Volumetric analysis of fluorodeoxyglucose positron emission tomography in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med (in press).
60. Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O'Sullivan F, Vernon CB, Link JM, Krohn KA. 2002a. Kinetic analysis of 2-[11C]Thymidine PET imaging studies of malignant brain tumors - Preliminary patient results. Molecular Imaging (in press).
61. Wells JM, Mankoff DA, Muzi M, O'Sullivan F, Eary JF, Spence AM, Krohn KA. 2002b. Kinetic analysis of 2-[11C]Thymidine PET imaging studies of malignant brain tumors: Compartmental model investigation and mathematical analysis. Molecular Imaging. (in press).
62. Wise RJS, Thomas DGT, Lammertsma AA, Rhodes CG. 1984. PET scanning of human brain tumors. Prog Exp Tumor Res 27:154-169.
63. Yoshimoto M, Waki A, Yonekura Y, Fujibayashi Y. 2001. Acetate and choline as cell growth markers provide different perspectives of lipid synthesis. J Nucl Med 42: 275p.